January 10, 2014
Daiichi Sankyo said on January 9 that it has submitted a new drug application (NDA) to the US FDA for the anticoagulant Savaysa (edoxaban). Savaysa, the oral direct factor Xa inhibitor, will be indicated for the prevention of strokes and...read more